Skip to content

Search

The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-The Kidstherapy

High medication literacy is the basis of rational medication application and is essential for the management of severe adverse drug reactions. The objective of the present study was to assess the level of medication literacy and determine the association between medication literacy and skin adverse drug reactions in non-small-cell lung cancer (NSCLC) patients undergoing targeted epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-The Kids) therapy.

Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia

Symptomatic methotrexate-related central neurotoxicity (MTX neurotoxicity) is a severe toxicity experienced during acute lymphoblastic leukemia (ALL) therapy with potential long-term neurologic complications. Risk factors and long-term outcomes require further study.

Beyond the horizon: improving cancer outcomes for Indigenous children

Dr Jessica Buck, a researcher at The Kids Research Institute Australia Cancer Centre and a Kamilaroi woman, is on a mission to address the unique challenges faced by Aboriginal and Torres Strait Islander children with cancer.

Childhood cancers not on the rise in SA and NT, but disparity remains for Indigenous children in the NT

Despite national and global reports of rising incidences of cancer affecting children and young people, a new analysis has found rates of childhood cancer have remained unchanged over the last 30 years in South Australia and the Northern Territory.

Precision medicine offering new hope for kids with aggressive cancers

A world-first study involving more than 100 cancer researchers and clinicians across Australia – including from The Kids Research Institute Australia and Perth Children’s Hospital – has shown that precision medicine can significantly improve outcomes for children with high-risk cancer.

WA-based cancer pharmaceutical start-up secures CUREator funding

Researchers dedicated to developing the first cancer immunotherapy tablet have been boosted by a $374,000 CUREator top-up funding grant.

Lab results confirm promise of new immunotherapy gel for kids cancer

Newly published research from The Kids Research Institute Australia and The University of Western Australia has found a gel applied during surgery to treat sarcoma tumours is both safe and highly effective at preventing the cancer from growing back.

Raine Foundation grants support exciting projects in childhood cancer and newborn infections

Two The Kids Research Institute Australia researchers have been awarded prestigious grants from the Raine Medical Research Foundation for projects in childhood cancer and newborn infection control.

Telethon supports vital child health research projects

The generous support of West Australians through Channel 7’s Telethon Trust will help support crucial child health research at The Kids Research Institute Australia in 2022.

Researchers narrow down field of new treatments for most common childhood brain cancer

Cancer researchers have narrowed-down the field of immunotherapy drugs which could be used to tackle a form of childhood brain cancer.